Researchers have discovered a new biological pathway in inflammatory bowel disease (IBD) and related conditions that can be targeted using existing drugs. About 5% of the world’s population are currently affected by an autoimmune disease, such as IBD, the umbrella term for Crohn’s disease and ulcerative… Read More
Kiave Yune Ho Wang Yin, PhD, Chief Business Officer at TransCure bioServices explores how humanized mouse models can be used to develop more relevant preclinical studies for IBD treatments and ultimately increase the likelihood of a treatment’s success in clinical trials. Inflammatory bowel diseases (IBDs), including Crohn’s… Read More
Biotechnology company Galapagos will in-license drug targets for inflammatory bowel disease (IBD) which were discovered using a biology platform developed by Scipher Medicine. The move follows a deal Galapagos and Scipher Medicine made in 2020 to jointly validate a suite of novel IBD targets discovered by Scipher’s Spectra platform. Under… Read More
Precision medicine technologies company Iterative Scopes has acquired two clinical trial optimisation companies focused on streamlining and accelerating the drug development process for inflammatory bowel disease (IBD). The company has acquired Clinical Research Strategy Group, LLC and Precision Research (CRSG/Precision) in an effort to bolster its efforts… Read More
